CFB and prostate cancer: Of translational relevance, recent studies have shown that galllein, a Gbg subunit signaling inhibitor, was capable of inhibiting the metastatic spread of prostate cancer cells expressing OR51E2 and, exposed to b-ionone, its odorant ligand [45].